IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-44786-2.html
   My bibliography  Save this article

Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy

Author

Listed:
  • Jingjing Ren

    (Yale School of Medicine)

  • Xiaofeng Liao

    (Yale School of Medicine)

  • Julia M. Lewis

    (Yale School of Medicine)

  • Jungsoo Chang

    (Yale School of Medicine)

  • Rihao Qu

    (Yale School of Medicine)

  • Kacie R. Carlson

    (Yale School of Medicine)

  • Francine Foss

    (Yale School of Medicine)

  • Michael Girardi

    (Yale School of Medicine)

Abstract

Current treatments for T cell malignancies encounter issues of disease relapse and off-target toxicity. Using T cell receptor (TCR)Vβ2 as a model, here we demonstrate the rapid generation of an off-the-shelf allogeneic chimeric antigen receptor (CAR)-T platform targeting the clone-specific TCR Vβ chain for malignant T cell killing while limiting normal cell destruction. Healthy donor T cells undergo CRISPR-induced TRAC, B2M and CIITA knockout to eliminate T cell-dependent graft-versus-host and host-versus-graft reactivity. Second generation 4-1BB/CD3zeta CAR containing high affinity humanized anti-Vβ scFv is expressed efficiently on donor T cells via both lentivirus and adeno-associated virus transduction with limited detectable pre-existing immunoreactivity. Our optimized CAR-T cells demonstrate specific and persistent killing of Vβ2+ Jurkat cells and Vβ2+ patient derived malignant T cells, in vitro and in vivo, without affecting normal T cells. In parallel, we generate humanized anti-Vβ2 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) by Fc-engineering for NK cell ADCC therapy.

Suggested Citation

  • Jingjing Ren & Xiaofeng Liao & Julia M. Lewis & Jungsoo Chang & Rihao Qu & Kacie R. Carlson & Francine Foss & Michael Girardi, 2024. "Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
  • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-44786-2
    DOI: 10.1038/s41467-024-44786-2
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-44786-2
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-024-44786-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Joseph A. Fraietta & Christopher L. Nobles & Morgan A. Sammons & Stefan Lundh & Shannon A. Carty & Tyler J. Reich & Alexandria P. Cogdill & Jennifer J. D. Morrissette & Jamie E. DeNizio & Shantan Redd, 2018. "Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells," Nature, Nature, vol. 558(7709), pages 307-312, June.
    2. Killian S. Hanlon & Benjamin P. Kleinstiver & Sara P. Garcia & Mikołaj P. Zaborowski & Adrienn Volak & Stefan E. Spirig & Alissa Muller & Alexander A. Sousa & Shengdar Q. Tsai & Niclas E. Bengtsson & , 2019. "High levels of AAV vector integration into CRISPR-induced DNA breaks," Nature Communications, Nature, vol. 10(1), pages 1-11, December.
    3. Fanlin Li & Huihui Zhang & Wanting Wang & Puyuan Yang & Yue Huang & Junshi Zhang & Yaping Yan & Yuan Wang & Xizhong Ding & Jie Liang & Xinyue Qi & Min Li & Ping Han & Xiaoqing Zhang & Xin Wang & Jiang, 2022. "T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lisa Maria Riedmayr & Klara Sonnie Hinrichsmeyer & Stefan Bernhard Thalhammer & David Manuel Mittas & Nina Karguth & Dina Yehia Otify & Sybille Böhm & Valentin Johannes Weber & Michael David Bartosche, 2023. "mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    2. Raed Ibraheim & Phillip W. L. Tai & Aamir Mir & Nida Javeed & Jiaming Wang & Tomás C. Rodríguez & Suk Namkung & Samantha Nelson & Eraj Shafiq Khokhar & Esther Mintzer & Stacy Maitland & Zexiang Chen &, 2021. "Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo," Nature Communications, Nature, vol. 12(1), pages 1-17, December.
    3. Xiangjun He & Zhenjie Zhang & Junyi Xue & Yaofeng Wang & Siqi Zhang & Junkang Wei & Chenzi Zhang & Jue Wang & Brian Anugerah Urip & Chun Christopher Ngan & Junjiang Sun & Yuefeng Li & Zhiqian Lu & Hui, 2022. "Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    4. Milan Gautam & Antony Jozic & Grace Li-Na Su & Marco Herrera-Barrera & Allison Curtis & Sebastian Arrizabalaga & Wayne Tschetter & Renee C. Ryals & Gaurav Sahay, 2023. "Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    5. Jianhang Yin & Kailun Fang & Yanxia Gao & Liqiong Ou & Shaopeng Yuan & Changchang Xin & Weiwei Wu & Wei-wei Wu & Jiaxu Hong & Hui Yang & Jiazhi Hu, 2022. "Safeguarding genome integrity during gene-editing therapy in a mouse model of age-related macular degeneration," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    6. Ron Baik & M. Kyle Cromer & Steve E. Glenn & Christopher A. Vakulskas & Kay O. Chmielewski & Amanda M. Dudek & William N. Feist & Julia Klermund & Suzette Shipp & Toni Cathomen & Daniel P. Dever & Mat, 2024. "Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    7. Meagan R. Rollins & Jackson F. Raynor & Ebony A. Miller & Jonah Z. Butler & Ellen J. Spartz & Walker S. Lahr & Yun You & Adam L. Burrack & Branden S. Moriarity & Beau R. Webber & Ingunn M. Stromnes, 2023. "Germline T cell receptor exchange results in physiological T cell development and function," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    8. Jianli Tao & Qi Wang & Carlos Mendez-Dorantes & Kathleen H. Burns & Roberto Chiarle, 2022. "Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    9. Nan Li & Alex Quan & Dan Li & Jiajia Pan & Hua Ren & Gerard Hoeltzel & Natalia Val & Dana Ashworth & Weiming Ni & Jing Zhou & Sean Mackay & Stephen M. Hewitt & Raul Cachau & Mitchell Ho, 2023. "The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    10. Eriya Kenjo & Hiroyuki Hozumi & Yukimasa Makita & Kumiko A. Iwabuchi & Naoko Fujimoto & Satoru Matsumoto & Maya Kimura & Yuichiro Amano & Masataka Ifuku & Youichi Naoe & Naoto Inukai & Akitsu Hotta, 2021. "Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice," Nature Communications, Nature, vol. 12(1), pages 1-13, December.
    11. Changchang Xin & Jianhang Yin & Shaopeng Yuan & Liqiong Ou & Mengzhu Liu & Weiwei Zhang & Jiazhi Hu, 2022. "Comprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    12. Jianli Tao & Daniel E. Bauer & Roberto Chiarle, 2023. "Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    13. Xiang Meng & Ruixuan Jia & Xinping Zhao & Fan Zhang & Shaohong Chen & Shicheng Yu & Xiaozhen Liu & Hongliang Dou & Xuefeng Feng & Jinlu Zhang & Ni Wang & Boling Xu & Liping Yang, 2024. "In vivo genome editing via CRISPR/Cas9-mediated homology-independent targeted integration for Bietti crystalline corneoretinal dystrophy treatment," Nature Communications, Nature, vol. 15(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-44786-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.